Dig Dis Sci

1. MAKOVICH Z, Radosavljevic I, Chapyala S, Handley G, et al
   Rationale for Hepatitis C Virus Treatment During Hematopoietic Stem Cell Transplant in the Era of Novel Direct-Acting Antivirals.
   Dig Dis Sci. 2024 Jul 11. doi: 10.1007/s10620-024-08541.
   

   >> Share

   
   

   
   J Hepatol

2. MINAMI T, Fujishiro M, Tateishi R
   Reply to: "Validation of SMART Model for HCC Risk stratification in genotype -4 HCV Patients following SVR and its comparison with GES score".
   J Hepatol. 2024 Jul 9:S0168-8278(24)02361-4. doi: 10.1016/j.jhep.2024.
   

   >> Share

   
   
3. KUNDU J, Le HT, Logan M, Hockman D, et al
   Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone.
   J Hepatol. 2024 Jul 8:S0168-8278(24)02335-3. doi: 10.1016/j.jhep.2024.
   

   >> Share

   
   

   
   J Med Virol

4. CASTRO V, Calvo G, Oliveros JC, Perez-Del-Pulgar S, et al
   Hepatitis C virus-induced differential transcriptional traits in host cells after persistent infection elimination by direct-acting antivirals in cell culture.
   J Med Virol. 2024;96:e29787.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share